人参皂苷Rg1
脂肪变性
纤维化
钙
内科学
化学
内分泌学
人参皂甙
肝纤维化
药理学
肝纤维化
信号转导
医学
脂肪变
钙信号传导
肾
癌症研究
钙结合蛋白
脂肪肝
作者
Haoyu Liang,Yulu Qian,Fujie Diao,Jinyao Bo,Lei Fan,Xing Zhu,Tanzhen Xu,Weizu Li
标识
DOI:10.1016/j.jphs.2026.06.009
摘要
Hepatic steatosis and fibrosis represent major complications of type 2 diabetes mellitus (T2DM) with limited therapeutic options. Ginsenoside Rg1, a bioactive constituent of Panax ginseng, exhibits hepatoprotective properties, but its mechanism in diabetic liver injury remains unclear. The transient receptor potential canonical 6 (TRPC6) channel is activated in metabolic disorders and promotes fibrosis. We hypothesized that Rg1 alleviates T2DM-associated liver injury by inhibiting TRPC6-mediated calcium signaling. In vivo, T2DM mice were treated with Rg1 and/or Trpc6 knockout. In vitro, HepG2 cells were exposed to high glucose plus palmitic acid (HG + PA) with Rg1, the TRPC6 inhibitor BI-749327, or the activator OAG. Both Rg1 and Trpc6 knockout ameliorated T2DM-induced liver damage, reducing steatosis and collagen deposition. Mechanistically, they downregulated hepatic TRPC6, calcineurin, and thioredoxin-interacting protein (TXNIP), and inhibited nuclear translocation of carbohydrate response element-binding protein (ChREBP), thereby suppressing NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation. In vitro, Rg1 and BI-749327 attenuated HG + PA-induced calcium overload, lipid accumulation, inflammation, mitochondrial dysfunction, and fibrotic activation, which were significantly abrogated by OAG. Our findings identify Rg1 as a promising agent for T2DM-associated hepatic complications via inhibiting TRPC6-mediated calcium signaling, highlighting TRPC6 as a novel therapeutic target.
科研通智能强力驱动
Strongly Powered by AbleSci AI